NCT07358923Not yet recruiting
Accuracy of Modified Milan Ultrasound Criteria in Assessing Disease Activity and Severity in Moderate-to-Severe Ulcerative Colitis: a Pilot Study
Source: ClinicalTrials.gov · Last updated 22 Jan 2026
Brief summary (registry, in English)
Longitudinal prospective monocentric observational study in which patients to start Mirikizumab for normal clinical practice will be followed for 24 weeks. Based on the findings in the comparison between US (IUS and TPUS) and endoscopy, the study aim is to build up a modified MUC (Milan Ultrasound Criteria) scoring system taking each colonic segment and the rectum into account, developing non-invasive quantitative ultrasound-based criteria to identify patients with active UC and assess its severity.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 25 (estimated)
- First submitted
- 14 Jan 2026
- Start date
- Feb 2026
- Primary completion date
- Oct 2026
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Ulcerative colitis
- NCT number
- NCT07358923
What you commit to
- Study type: Observational
- Planned participants: 25
- From Feb 2026 to the primary completion date, Oct 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with unclassified colitis or other gastrointestinal conditions
- Patients with current infections or other severe comorbidity, including liver, kidney or cardiac failure, which contraindicate the initiation of advanced therapy
Age
- Age \< 18 years
Other
- Patients unable or unwilling to provide consent
Who the study is looking for
- Age ≥ 18 years
- Confirmed diagnosis of UC according to ECCO guidelines
- Patients with active moderate-to-severe disease defined as MES
- ≥ 2
- Patients undergoing advanced therapies with mirikizumab according to clinical judgement
- Patients who provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.